先进混合闭环系统在儿童和青少年1型糖尿病队列中的持续有效性:一项为期1年的真实世界研究
这项多中心、纵向真实世界研究纳入368例开始使用SmartGuard技术的1型糖尿病儿童和青少年,评估MiniMed 780G使用12个月内的血糖指标及血糖结局预测因素。使用自动模式15天后除低于范围时间和变异系数外所有血糖指标较基线改善(P<0.001);1年后TIR仍显著高于基线(75.3% vs 62.8%,P<0.001),研究期间平均HbA1c低于前一年(6.9±0.6% vs 7.4±0.9%,P<0.001)。
要点
- 使用MiniMed 780G自动模式15天后,除低于范围时间(P=0.113)和变异系数(P=0.330)外,所有血糖指标较基线改善(P<0.001)。
- 使用1年后TIR仍显著高于基线(75.3% vs 62.8%,P<0.001),研究期间平均HbA1c低于前一年(6.9±0.6% vs 7.4±0.9%,P<0.001)。
- 基线HbA1c>8%者TIR改善更明显(从54.3%升至72.3%)。
核心结论
- 本研究强调MiniMed 780G在1型糖尿病青少年中具有持续有效性,研究结果提示即使治疗参与度低的儿童和青少年也可能从SmartGuard技术中获益。
研究设计与样本
- 多中心、纵向真实世界研究,于2020年6月至2022年6月期间招募368例开始使用SmartGuard技术的1型糖尿病儿童和青少年。
- 在15天导入期(基线)、自动模式激活后2周及每3个月收集动态血糖图谱数据,并评估 covariates 对使用MiniMed 780G 1年后血糖结局的影响。
主要发现
- 使用自动模式15天后,除低于范围时间(P=0.113)和变异系数(P=0.330)外,所有血糖指标较基线改善(P<0.001)。
- 使用1年后TIR仍显著高于基线(75.3% vs 62.8%,P<0.001)。
- 研究期间平均HbA1c低于前一年(6.9±0.6% vs 7.4±0.9%,P<0.001)。
- 严格范围(70-140 mg/dL)内时间占比为51.1%,血糖风险指数为27.6。
- 基线HbA1c>8%者TIR改善更明显(从54.3%升至72.3%)。
关键数值与推荐
- 较高TIR水平与较少的自动校正大剂量次数相关(P<0.001)。
- 较高TIR水平与较少的SmartGuard退出次数相关(P=0.021)。
- 较高TIR水平与较长的自动模式时间相关(P=0.030)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use. RESEARCH DESIGN AND METHODS: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed. RESULTS: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA1c) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70-140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3% to 72.3%). CONCLUSIONS: Our study highlights the sustained effectiveness of MiniMed 780G among youth with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology.
引用
- Passanisi S, Salzano G, Bombaci B, et al. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study. Diabetes Care. 2024. PMID: 38626260. doi:10.2337/dc23-2311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。